P/E ratio for Evoke Pharma (EVOK)
P/E ratio as of May 2024 (TTM): -0.1907
According to Evoke Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.190678. At the end of 2022 the company had a P/E ratio of -1.02.
P/E ratio history for Evoke Pharma from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.02 | -51.55% |
| 2021 | -2.10 | -57.77% |
| 2020 | -4.96 | 1.07% |
| 2019 | -4.91 | -8.94% |
| 2018 | -5.39 | 100.38% |
| 2017 | -2.69 | 69.15% |
| 2016 | -1.59 | -8.9% |
| 2015 | -1.75 | -35.19% |
| 2014 | -2.69 | -52.08% |
| 2013 | -5.62 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ANI Pharmaceuticals ANIP | -140 | 73,545.62% | 🇺🇸 USA |
 Amphastar Pharmaceuticals AMPH | 19.6 | -10,401.61% | 🇺🇸 USA |
 Aerie Pharmaceuticals AERI | -20.3 | 10,563.68% | 🇺🇸 USA |
 Ironwood Pharmaceuticals
IRWD | -1.32 | 590.06% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.